Themis Medicare Peer Comparison

Themis Medicare Ltd. exhibits moderate growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it is not the highest performer in any category, it maintains a solid position with low debt and reasonable EBITDA margins, suggesting stability. However, several peers outperform it in growth and return metrics, indicating competitive pressure.

• • Themis Medicare has a moderate revenue growth of 7.74% YoY, but lower than several peers.
• • It has a relatively low PE ratio of 38.57, but this does not translate into high profitability, with a ROE of 7.65%.
• • The company maintains a low debt-to-equity ratio of 0.2061, suggesting financial stability.

• • Mankind Pharma Ltd.: Highest revenue growth YoY at 18.12% and strong profitability metrics.
• • Cipla Ltd.: Best overall balance of growth, profitability, and low valuation metrics.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability with a ROE of 21.76% and attractive PEG of 0.19.